{"page":{"totalFilteredElements":335},"studies":[{"active":true,"description":"NIcht-interventionelle Unbedenklichkeitsstudie zur Vertr&#228;glichkeit und Sicherheit von <b>Octagam 5% und Octagam 10%</b>.","eudractNumber":null,"id":2824,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2014-06-01T12:19:18+02:00","shortTitle":"GAM-33 Octagam","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":11341,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-01-28T09:00:35+01:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":6546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-04-01T11:55:14+02:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"panORA &#8211; panzyga&#174; Observation in Real-World Application:<br />Nicht-interventionelle Studie (NIS) zur Vertr&#228;glichkeit und<br />Wirksamkeit von panzyga&#174; (GAM-38)","eudractNumber":null,"id":12337,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-07-31T08:49:08+02:00","shortTitle":"GAM-38","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Long-Term Follow up Protocol for subjects treated with gene-modified T Cells<br />","eudractNumber":"2017-001465-24","id":5382,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03435796","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2019-01-10T13:02:46+01:00","shortTitle":"GC-LTFU-001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>GENERATE &#8211; Next GENERATion of GynEcological Surgery &#8211; Robotic Assisted Surgery in Gynecological Indications &#8211; A Prospective, Non-Interventional, Multi-Center, Post Market</div><div>Clinical Study</div>","eudractNumber":null,"id":12271,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05867927","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-08-18T08:34:07+02:00","shortTitle":"GENERATE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"GISAR - German Interdisciplinary Sarcoma Registry","eudractNumber":null,"id":6496,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04122872","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-04-27T11:37:36+02:00","shortTitle":"GISAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11855,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-10T08:43:49+01:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11945,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-01T08:48:53+02:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen und verwandter Erkrankungen in Verbindung mit einer prospektiven Biomaterialsammlung","eudractNumber":null,"id":1513,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[],"nctNumber":"NCT02872987","phase":null,"recruitmentStart":"2009-09-15T08:32:21+02:00","shortTitle":"GMALL Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}